NASDAQ: MTVA
MetaVia Inc.CIK 0001638287 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (TLRY 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade MTVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
MetaVia reports 9.1% weight loss in Phase 1 obesity trial for DA-1726, advances pipeline
4 material changes detected. Sign up free to read the summary.
MetaVia stockholders approve reverse stock split at 1-for-5 to 1-for-22 ratio
3 material changes detected. Sign up free to read the summary.
MetaVia presents Phase 1 data on dual-receptor obesity/liver drug DA-1726 at EASL
2 material changes detected. Sign up free to read the summary.
MetaVia obesity and diabetes drug data accepted for ADA 2026 conference presentations
2 material changes detected. Sign up free to read the summary.
net income -$3.8M. MetaVia removes material weakness disclosures; vanoglipel Phase 2a timeline slips one year
5 material changes detected. Sign up free to read the summary.
net income -$13.0M. MetaVia extends cash runway to Q4 2026 via + equity warrant overhang drops 53.0%
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 6, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(Unaudited - In thousands, except share and per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | 3,478 | 2,320 | 5,579 | 4,647 |
| General and administrative | 1,907 | 1,981 | 3,831 | 3,540 |
| Total operating expenses | 5,385 | 4,301 | 9,410 | 8,187 |
| Loss from operations | (5,385) | (4,301) | (9,410) | (8,187) |
| Other income (expense) | ||||
| (Loss) gain from change in fair value of warrant liabilities | (4) | 160 | 113 | 247 |
| Interest income, net | 73 | 146 | 158 | 274 |
| Total other income | 69 | 306 | 271 | 521 |
| Loss before income taxes | (5,316) | (3,995) | (9,139) | (7,666) |
| Provision for income taxes | — | — | — | — |
| Net loss | (5,316) | (3,995) | (9,139) | (7,666) |
| Loss per share of common stock, basic and diluted | (0.90) | (2.87) | (1.69) | (6.59) |
| Weighted average shares of common stock, basic and diluted | 5,931,875 | 1,389,753 | 5,398,683 | 1,162,692 |
Condensed Consolidated Balance Sheets (Unaudited)
(Unaudited - In thousands, except share and per share amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 12,634 | 10,278 |
| Prepaid expenses and other current assets | 433 | 597 |
| Total current assets | 13,067 | 10,875 |
| Property and equipment, net | 8 | 17 |
| Right-of-use asset | 175 | 210 |
| Other assets | 21 | 21 |
| Total assets | 13,271 | 11,123 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | 921 | 1,060 |
| Clinical trial accrued liabilities | 2,825 | 79 |
| Accrued expenses and other current liabilities | 606 | 993 |
| Warrant liabilities | 23 | 136 |
| Related party payable | 1,897 | 3,312 |
| Lease liability, short-term | 74 | 68 |
| Total current liabilities | 6,346 | 5,648 |
| Lease liability, long-term | 103 | 142 |
| Total liabilities | 6,449 | 5,790 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value per share, 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,575,656 and 2,308,294 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 7 | 2 |
| Additional paid–in capital | 164,784 | 154,161 |
| Accumulated deficit | (157,969) | (148,830) |
| Total stockholders’ equity | 6,822 | 5,333 |
| Total liabilities and stockholders’ equity | 13,271 | 11,123 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Unaudited - In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | (9,139) | (7,666) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 230 | 243 |
| Non-cash professional services expenses | 144 | — |
| Non-cash lease charge (credit) | 2 | (1) |
| Depreciation | 9 | 9 |
| Gain from change in fair value of warrant liabilities | (113) | (247) |
| Change in operating assets and liabilities | ||
| Prepaid expenses and other assets | 164 | (671) |
| Accounts payable | (261) | (1,348) |
| Accrued and other liabilities | 944 | 1,795 |
| Net cash used in operating activities | (8,020) | (7,886) |
| Investing activities | ||
| Purchases of property and equipment | — | (2) |
| Net cash used in investing activities | — | (2) |
| Financing activities | ||
| Proceeds from the issuance of common stock and warrants under an underwritten public offering | 9,316 | — |
| Payment of issuance costs in connection with the sale of common stock and warrants under an underwritten public offering | (2,179) | — |
| Proceeds from the issuance of common stock under an at the market offering agreement | 913 | — |
| Payment of issuance costs in connection with the sale of common stock under an at the market offering agreement | (94) | — |
| Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering | — | 9,996 |
| Payment of issuance costs in connection with the sale of common stock and warrants under the securities purchase agreements from a private placement offering | — | (530) |
| Proceeds from exercise of warrants | 2,420 | 6 |
| Payment of employee withholding taxes related to shares withheld from vested restricted stock units | — | (12) |
| Net cash provided by financing activities | 10,376 | 9,460 |
| Net increase in cash and cash equivalents | 2,356 | 1,572 |
| Cash and cash equivalents at beginning of period | 10,278 | 16,017 |
| Cash and cash equivalents at end of period | 12,634 | 17,589 |
| Supplemental non-cash investing and financing transactions | ||
| Unpaid issuance costs | 122 | 344 |
Amounts as printed on the EDGAR/iXBRL face — (Unaudited - In thousands, except share and per share amounts); (Unaudited - In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗